Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Lohmann

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Journal of Neuro-Oncology|July 19, 2022
Static FET PET radiomics for the differentiation of treatment-related changes from glioma progressionMarguerite Müller, Oliver Winz, Robin Gutsche, et al.
Neuro-Oncology|March 11, 2024
Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO groupNorbert Galldiks, Timothy J Kaufmann, Philipp Vollmuth, et al.
Molecular Imaging and Biology|October 17, 2023
Assessment of Brain Tumour Perfusion Using Early-Phase <sup>18</sup>F-FET PET: Comparison with Perfusion-Weighted MRIChristian P Filss, Julian Cramer, Saskia Löher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PETJan-Michael Werner, Johannes Weller, Garry Ceccon, et al.
Neuro-Oncology Advances|March 14, 2025
Functional connectivity between tumor region and resting-state networks as imaging biomarker for overall survival in recurrent gliomas diagnosed by <i>O</i>-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine PETMichel Friedrich, Jan-Michael Werner, Joachim P Steinbach, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 9, 2020
Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine PETElena K Bauer, Gabriele Stoffels, Tobias Blau, et al.
Neuro-Oncology|December 22, 2021
Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastasesAnna-Katharina Meißner, Robin Gutsche, Norbert Galldiks, et al.
Nuklearmedizin. Nuclear Medicine|May 21, 2026
Updated Procedure Guideline of the German Society of Nuclear Medicine for Amyloid Brain PET Imaging 3.0Henryk Barthel, Matthias Brendel, Nathalie Albert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
Borderline Findings in <i>O</i>-(2-[<sup>18</sup>F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical PracticeKarl-Josef Langen, Gabriele Stoffels, Christian P Filss, et al.
Clinical Nuclear Medicine|January 14, 2025
The Value of Multidisciplinary Neuro-oncological Tumor Boards to Increase the Accuracy of FET PET for Identifying Brain Tumor RelapseGarry S Ceccon, Jan-Michael Werner, Maximilian I Ruge, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Journal of Neuro-Oncology|July 19, 2022
Static FET PET radiomics for the differentiation of treatment-related changes from glioma progressionMarguerite Müller, Oliver Winz, Robin Gutsche, et al.
Neuro-Oncology|March 11, 2024
Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO groupNorbert Galldiks, Timothy J Kaufmann, Philipp Vollmuth, et al.
Molecular Imaging and Biology|October 17, 2023
Assessment of Brain Tumour Perfusion Using Early-Phase <sup>18</sup>F-FET PET: Comparison with Perfusion-Weighted MRIChristian P Filss, Julian Cramer, Saskia Löher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PETJan-Michael Werner, Johannes Weller, Garry Ceccon, et al.
Neuro-Oncology Advances|March 14, 2025
Functional connectivity between tumor region and resting-state networks as imaging biomarker for overall survival in recurrent gliomas diagnosed by <i>O</i>-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine PETMichel Friedrich, Jan-Michael Werner, Joachim P Steinbach, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 9, 2020
Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine PETElena K Bauer, Gabriele Stoffels, Tobias Blau, et al.
Neuro-Oncology|December 22, 2021
Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastasesAnna-Katharina Meißner, Robin Gutsche, Norbert Galldiks, et al.
Nuklearmedizin. Nuclear Medicine|May 21, 2026
Updated Procedure Guideline of the German Society of Nuclear Medicine for Amyloid Brain PET Imaging 3.0Henryk Barthel, Matthias Brendel, Nathalie Albert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
Borderline Findings in <i>O</i>-(2-[<sup>18</sup>F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical PracticeKarl-Josef Langen, Gabriele Stoffels, Christian P Filss, et al.
Clinical Nuclear Medicine|January 14, 2025
The Value of Multidisciplinary Neuro-oncological Tumor Boards to Increase the Accuracy of FET PET for Identifying Brain Tumor RelapseGarry S Ceccon, Jan-Michael Werner, Maximilian I Ruge, et al.
Pageof 14